Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04663438

Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

Extensive-stage Small Cell Lung Cancer Clinical Trial

Official title:
First-line Atezolizumab Plus Chemotherapy in Patients With Extensive-stage Small-cell Lung Cancer:a Real World,Single Arm,Multicenter,Prospective Study in China

Clinical Trial Summary

The study is a prospective,multi-center,single arm,real world study to evaluate safety and performance of Atezolizumab plus chemotherapy in patients with extensive-stage small-cell lung cancer,and also to explore potential biomarkers for Immune-related Adverse Events.

Clinical Trial Description

In 2018,the results of IMpower 133 were reported on WCLC.Meanwhile,the data was published in NEJM.Atezolizumab combined with carboplatin and etoposide for extensive stage small cell lung cancer was recommended as the first by NCCN guidelines quickly. Atezolizumab plus chemotherapy was approved by NMPA on Feb 13,2020,making Atezolizumab for 1L ES-SCLC in China. Real world study can reflect the efficacy and safety of treatment in clinical practice.Based on the research of public database,the prospective cohort study had been reported,but the study based on Chinese patients still left weak point. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04663438
Study type Observational
Source Peking Union Medical College Hospital
Contact Li Zhang, PhD
Phone 16601139836
Email pumchzhangli@163.com
Status Recruiting
Phase
Start date June 30, 2020
Completion date May 30, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05509699 - Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05975944 - Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT04562337 - A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer Phase 2
Completed NCT00616109 - Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Phase 2
Active, not recruiting NCT04373369 - Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04254471 - This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients Phase 2/Phase 3
Active, not recruiting NCT04774380 - Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Phase 3
Active, not recruiting NCT01555710 - Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Phase 3
Completed NCT00682981 - A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase 1/Phase 2
Recruiting NCT04397003 - Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04702880 - A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04487756 - Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer Phase 1/Phase 2
Recruiting NCT03135977 - Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy Phase 2
Completed NCT03913455 - Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT03971214 - PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT04101357 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Phase 1/Phase 2
Completed NCT04636762 - A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) Phase 2
Not yet recruiting NCT04404543 - A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer Phase 1
Completed NCT02323737 - Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer Phase 2
Completed NCT03911219 - Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy